Successful Treatment of Lactobacillus rhamnosus Endocarditis With Intravenous Daptomycin: A Case Report and Literature Review.

2026-01
Case reports in infectious diseases 2026(1)

PubMed: 41607419
DOI: 10.1155/crdi/9295802

Study Design

Type: Case Report
Population: a case of Lactobacillus rhamnosus endocarditis
Methods: 6 weeks of intravenous daptomycin

Lactobacilli are Gram-positive, facultatively aerobic, rod-shaped bacteria that are a normal part of the human microbiota and rarely cause infections in immunocompetent hosts. Lactobacillus casei and Lactobacillus rhamnosus are the most common human pathogens within this genus and are also frequently used in probiotics. Both species are inherently resistant to vancomycin, and penicillin-sometimes in combination with aminoglycosides-remains the primary treatment for infections caused by these organisms. Management becomes particularly challenging in patients with severe penicillin allergies, such as anaphylaxis. Although daptomycin has demonstrated in vitro activity against these pathogens, clinical data on its use are limited. Here, we present a case of Lactobacillus rhamnosus endocarditis successfully treated with 6 weeks of intravenous daptomycin.

Research Insights

Supplement	Dose	Health Outcome	Effect Type	Effect Size	Source
Lactobacillus casei rhamnosus	—	Resolved Endocarditis	Beneficial	Moderate	View source Here, we present a case of Lactobacillus rhamnosus endocarditis successfully treated with 6 weeks of intravenous daptomycin.
Lactobacillus rhamnosus	—	Resolved Endocarditis	Beneficial	Moderate	View source Here, we present a case of Lactobacillus rhamnosus endocarditis successfully treated with 6 weeks of intravenous daptomycin.